KRAS and neoplasm: Recent studies have also shown that molecular and biochemical markers, such as KRAS mutation, p53 mutations, microsatellite instability (MSI), and disseminated circulating tumor cells, may be used more precisely to define prognosis and predict benefit of neoadjuvant treatment in CRC [45].